ストックスクリーナーアプリを入手
143.72
0.75%
-1.09
前日終値:
$144.81
開ける：
$145.24
24時間の取引高:
4.19M
Relative Volume:
0.61
時価総額：
$178.21B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
19.56
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
-4.82%
1か月 パフォーマンス:
+5.86%
6か月 パフォーマンス:
-1.56%
1年 パフォーマンス:
+21.94%
1日の値動き範囲:
$143.50
$145.99
1週間の範囲:
$143.50
$148.65
52週間の値動き範囲:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
143.72 | 178.21B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,115.70 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
265.58 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
257.12 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
143.93 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
137.16 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD - marketbeat.com
RSU vesting leaves Gilead (NASDAQ: GILD) CMO with 270 new shares after tax - Stock Titan
Gilead Sciences stock gains support as HSBC lifts price target to USD 175 - ad-hoc-news.de
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales - finance.yahoo.com
New Research Center Boosts Gilead's Investment In California - Business Facilities
Why is Gilead Sciences (NASDAQ:GILD) stock in focus today? - Kalkine Media
Gilead Sciences Share Price Today (GILD) | Live Chart, News & Stock Market - TechGraph
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD - marketbeat.com
Key facts: Gilead Sciences, Inc. BIKTARVY ~52% U.S. HIV; HSBC PT $175 - TradingView
Gilead Sciences stock heads into the open after a 0.24% gain - ad-hoc-news.de
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Benzinga
Gilead Sciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: broader growth - Investing.com Nigeria
GILD Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth - marketbeat.com
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
In draft guidance, NICE rebuffs Gilead's twice-a-year PrEP med for national coverage - fiercepharma.com
HSBC Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - marketbeat.com
HSBC Adjusts Price Target on Gilead Sciences to $175 From $155, Keeps Buy Rating - moomoo.com
Tidal Investments LLC Raises Position in Gilead Sciences, Inc. $GILD - marketbeat.com
Gilead Sciences, Inc. $GILD Shares Acquired by National Pension Service - marketbeat.com
NICE says no to Gilead's lenacapavir for HIV PrEP - pharmaphorum
Gilead Sciences stock holds near highs as Q2 2026 EPS beats and new ex-dividend date nears - ad-hoc-news.de
Engineers Gate Manager LP Acquires Shares of 112,886 Gilead Sciences, Inc. $GILD - marketbeat.com
Allworth Financial LP Sells 8,687 Shares of Gilead Sciences, Inc. $GILD - marketbeat.com
Gilead Sciences stock heads into the open after a 0.7 percent dip - ad-hoc-news.de
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode - finance.yahoo.com
Gilead Sciences stock falls as investors reassess post-earnings rally - ad-hoc-news.de
Gilead launches research facility in US for new medicine development - finance.yahoo.com
NewEdge Advisors LLC Raises Holdings in Gilead Sciences, Inc. $GILD - marketbeat.com
How Bixlenvo Approval At Gilead Sciences (GILD) Has Changed Its Investment Story - simplywall.st
Gilead opens new building on existing Foster City campus - NBC Bay Area
Gilead National Ribbon Cutting Ceremony - Post Register
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights - finance.yahoo.com
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa
Assembly Bio stock gains after exercising Gilead profit option - Investing.com India
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Gilead Opens 182,000-Square-Foot Research Center in Foster City - Contract Pharma
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement - tradingkey.com
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines - Gilead Sciences
Gilead Sciences stock gains on fresh analyst buy rating and Q2 loss swing - AD HOC NEWS
Gilead Sciences Slides 3.4% as Investors Digest Prior Gains and Ongoing Pricing Risks - Moomoo
Gilead opens research center as $32 billion US build-out continues - The Pharma Letter
Gilead Sciences, Inc. $GILD Shares Purchased by Groupe la Francaise - marketbeat.com
California State Teachers Retirement System Has $30.47 Billion Stake in Gilead Sciences, Inc. $GILD - marketbeat.com
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market? - Yahoo Finance
[Press release] FDA approves Gilead’s Bixlenvo™, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens - European AIDS Treatment Group
Gilead Sciences stock gains after narrowing Q2 loss and firming 2026 guidance - AD HOC NEWS
Gilead Sciences, Inc. $GILD Holdings Raised by HighTower Advisors LLC - marketbeat.com
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $130.42 Million Position in Gilead Sciences, Inc. $GILD - marketbeat.com
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Option Exercise |
61.06 |
18,000 |
1,099,052 |
23,176 |
| WELTERS ANTHONY | Director |
Aug 26 '26 |
Sale |
148.62 |
18,000 |
2,675,220 |
12,894 |
2.14%
0.25%
大文字化:
|
ボリューム (24 時間):